Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro. (Q40460503)
Jump to navigation
Jump to search
scientific article published on July 2005
Language | Label | Description | Also known as |
---|---|---|---|
English | Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro. |
scientific article published on July 2005 |
Statements
1 reference
2 references
Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro. (English)
1 reference
1 reference
1 reference
Danilo Millimaggi
1 reference
Paola Muzi
1 reference
Claudio Festuccia
1 reference
1 July 2005
1 reference
1 reference
115
1 reference
4
1 reference
630-640
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference